|
You want them to take a look at our urgent-use/shortage drug compounding legislation. In the House that’s HR 167, for which we’re seeking additional co-sponsors. In the Senate, it’s the language of that House bill, which we’re looking to have added to the pandemic preparedness reauthorization bill taking shape in the Senate HELP Committee.
The legislation would make the 2020 temporary guidance on compounding COVID drugs permanent and would expand it to include any drugs that are listed as “currently in shortage” on the FDA’s drug shortage list. It would allow traditional compounders to prepare shortage drugs not only for hospitals but also for medical clinics if they cannot source needed drugs for in-clinic administration—say, for a cataract surgery—from the manufacturer or an outsourcing facility.
It would also require that FDA’s Drug Shortage list be supplemented by the drug shortage list maintained by the American Society of Health System Pharmacists, which is a better real-time indicator of national and regional drug shortages.
We’re making reaching out to your legislators quick and easy—the punch of just a button or two. We’ve pre-written the message for you, though you can certainly personalize it if you wish. And we’re using a platform that, based on your home address, will send the message to your members of Congress even if you don’t know exactly who they are or how to reach them.
It’s important for you to respond, so I’m giving you a heads-up: Pay attention to this one. Please.
– Anthony
Anthony Grzib is VP of quality and compliance, state-regulated pharmacies at Wedgewood Pharmacy in Swedesboro, New Jersey. You can reach him at agrzib@wedgewoodpharmacy.com.
| 
